Combating medical device fouling

Trends in Biotechnology

Volumn 32, Issue 3, 2014, Pages 140-146

  Harding, Jacqueline L ^a   Reynolds, Melissa M ^a,b  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Engineering Research Center and Hydraulics Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCOMPATIBLE MATERIALS; BIOFOULING; BIOTECHNOLOGY; EQUIPMENT CONTAMINATION; EQUIPMENT DESIGN; EQUIPMENT SAFETY; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS;

EID: 84894288310     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2013.12.004     Document Type: Review

References (79)

1. Donlan R.M. Problems of biofilms associated with medical devices and implants. Medical Biofilms 2003, 29-49. John Wiley.
2. Vertes A., et al. Analytical challenges of microbial biofilms on medical devices. Anal. Chem. 2012, 84:3858-3866.
3. Costerton J.W., et al. Bacterial biofilms: a common cause of persistent infections. Science 1999, 284:1318-1322.
4. Gilbert P., et al. Control of biofilms associated with implanted medical devices. Medical Biofilms 2003, 73-96. John Wiley.
5. Pitt W.G., et al. Sequential protein adsorption and thrombus deposition on polymeric biomaterials. J. Colloid Interface Sci. 1986, 111:343-362.
6. Keefer L.K. Biomaterials - thwarting thrombus. Nat. Mater. 2003, 2:357-358.
7. Walker J.T., et al. Biofilms past, present and future - new methods and control strategies in medicine. Medical Biofilms 2003, 255-278. John Wiley.
8. Jass J., et al. Microbial biofilms in medicine. Medical Biofilms 2003, 1-28. John Wiley.
9. Campoccia D., et al. A review of the biomaterials technologies for infection-resistant surfaces. Biomaterials 2013, 34:8533-8554.
10. Horbett T.A. Principles underlying the role of adsorbed plasma-proteins in blood interactions with foreign materials. Cardiovasc. Pathol. 1993, 2:S137-S148.
11. Packham M.A. The behavior of platelets at foreign surfaces. Proc. Soc. Exp. Biol. Med. 1988, 189:261-274.
12. Basu B., Nath S. Fundamentals of biomaterials and biocompatibility. Advanced Biomaterials 2009, 1-18. John Wiley.
13. Chen S.F., et al. Surface hydration: principles and applications toward low-fouling/nonfouling biomaterials. Polymer 2010, 51:5283-5293.
14. Li J., Kao W.J. Synthesis of polyethylene glycol (PEG) derivatives and PEGylated-peptide blopolymer conjugates. Biomacromolecules 2003, 4:1055-1067.
15. Francolini I., et al. Synthesis of biomimetic segmented polyurethanes as antifouling biomaterials. Acta Biomater. 2012, 8:549-558.
16. Privett B.J., et al. Antibacterial fluorinated silica colloid superhydrophobic surfaces. Langmuir 2011, 27:9597-9601.
17. Epstein A.K., et al. Liquid-infused structured surfaces with exceptional anti-biofouling performance. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:13182-13187.
18. Li J.S., et al. Hydrophobic liquid-infused porous polymer surfaces for antibacterial applications. ACS Appl. Mater. Interfaces 2013, 5:6704-6711.
19. Cheng G., et al. Inhibition of bacterial adhesion and biofilm formation on zwitterionic surfaces. Biomaterials 2007, 28:4192-4199.
20. Jiang S.Y., Cao Z.Q. Ultralow-fouling, functionalizable, and hydrolyzable zwitterionic materials and their derivatives for biological applications. Adv. Mater. 2010, 22:920-932.
21. Siedenbiedel F., Tiller J.C. Antimicrobial polymers in solution and on surfaces: overview and functional principles. Polymers 2012, 4:46-71.
22. Timofeeva L., Kleshcheva N. Antimicrobial polymers: mechanism of action, factors of activity, and applications. Appl. Microbiol. Biotechnol. 2011, 89:475-492.
23. Moore L.E., et al. In vitro study of the effect of cationic biocides on bacterial population dynamics and susceptibility. Appl. Environ. Microbiol. 2008, 74:4825-4834.
24. Murata H., et al. Permanent, non-leaching antibacterial surfaces - 2: how high density cationic surfaces kill bacterial cells. Biomaterials 2007, 28:4870-4879.
25. Jayakumar R., et al. Novel chitin and chitosan nanofibers in biomedical applications. Biotechnol. Adv. 2010, 28:142-150.
26. Rabea E.I., et al. Chitosan as antimicrobial agent: applications and mode of action. Biomacromolecules 2003, 4:1457-1465.
27. Sionkowska A. Current research on the blends of natural and synthetic polymers as new biomaterials: review. Prog. Polymer Sci. 2011, 36:1254-1276.
28. Zou P., et al. It takes walls and knights to defend a castle - synthesis of surface coatings from antimicrobial and antibiofouling polymers. J. Mater. Chem. 2012, 22:19579-19589.
29. Cao B., et al. The impact of structure on elasticity, switchability, stability and functionality of an all-in-one carboxybetaine elastomer. Biomaterials 2013, 34:7592-7600.
30. Green J.B.D., et al. Review of immobilized antimicrobial agents and methods for testing. Biointerphases 2011, 6:MR13-MR28.
31. Costa F., et al. Covalent immobilization of antimicrobial peptides (AMPs) onto biomaterial surfaces. Acta Biomater. 2011, 7:1431-1440.
32. Forbes S., et al. Comparative surface antimicrobial properties of synthetic biocides and novel human apolipoprotein E derived antimicrobial peptides. Biomaterials 2013, 34:5453-5464.
33. Waterhouse A., et al. In vivo biocompatibility of a plasma-activated, coronary stent coating. Biomaterials 2012, 33:7984-7992.
34. Bilek M.M.M., et al. Free radical functionalization of surfaces to prevent adverse responses to biomedical devices. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14405-14410.
35. Bazaka K., et al. Plasma-assisted surface modification of organic biopolymers to prevent bacterial attachment. Acta Biomater. 2011, 7:2015-2028.
36. Bazaka K., et al. Efficient surface modification of biomaterial to prevent biofilm formation and the attachment of microorganisms. Appl. Microbiol. Biotechnol. 2012, 95:299-311.
37. Hequet A., et al. Optimized grafting of antimicrobial peptides on stainless steel surface and biofilm resistance tests. Colloids Surf. B: Biointerfaces 2011, 84:301-309.
38. Wang B.L., et al. Construction of degradable multilayer films for enhanced antibacterial properties. ACS Appl. Mater. Interfaces 2013, 5:4136-4143.
39. Anderson J.M. Biological responses to materials. Annu. Rev. Mater. Res. 2001, 31:81-110.
40. Darouiche R.O. Current concepts - treatment of infections associated with surgical implants. N. Engl. J. Med. 2004, 350:1422-1429.
41. Neu H.C. The crisis in antibiotic-resistance. Science 1992, 257:1064-1073.
42. Stewart P.S., Costerton J.W. Antibiotic resistance of bacteria in biofilms. Lancet 2001, 358:135-138.
43. Hetrick E.M., Schoenfisch M.H. Reducing implant-related infections: active release strategies. Chem. Soc. Rev. 2006, 35:780-789.
44. Charville G.W., et al. Reduced bacterial adhesion to fibrinogen-coated substrates via nitric oxide release. Biomaterials 2008, 29:4039-4044.
45. Lu Y., et al. Shape- and nitric oxide flux-dependent bactericidal activity of nitric oxide-releasing silica nanorods. Small 2013, 9:2189-2198.
46. Mowery K.A., et al. Preparation and characterization of hydrophobic polymeric films that are thromboresistant via nitric oxide release. Biomaterials 2000, 21:9-21.
47. Privett B.J., et al. Examination of bacterial resistance to exogenous nitric oxide. Nitric Oxide 2012, 26:169-173.
48. Grainger D.W. Controlled-release and local delivery of therapeutic antibodies. Expert Opin. Biol. Ther. 2004, 4:1029-1044.
49. Simovic S., et al. Controlled drug release from porous materials by plasma polymer deposition. Chem. Commun. 2010, 46:1317-1319.
50. Zilberman M., Elsner J.J. Antibiotic-eluting medical devices for various applications. J. Control. Release 2008, 130:202-215.
51. Stefanini G.G., Holmes D.R. Drug-eluting coronary-artery stents. N. Engl. J. Med. 2013, 368:254-265.
52. Vasilev K., et al. Controlled release of levofloxacin sandwiched between two plasma polymerized layers on a solid carrier. ACS Appl. Mater. Interfaces 2011, 3:4831-4836.
53. Ruckh T.T., et al. Antimicrobial effects of nanofiber poly(caprolactone) tissue scaffolds releasing rifampicin. J. Mater. Sci. Mater. Med. 2012, 23:1411-1420.
54. Kakade S., Mani G. A comparative study of the effects of vitamin C, sirolimus, and paclitaxel on the growth of endothelial and smooth muscle cells for cardiovascular medical device applications. Drug Des. Dev. Ther. 2013, 7:529-544.
55. Palmer R.M.J., et al. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
56. Ignarro L.J. Biological actions and properties of endothelium-derived nitric-oxide formed and released from artery and vein. Circ. Res. 1989, 65:1-21.
57. Grisham M.B., et al. Nitric oxide I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation. Am. Physiol. Soc. 1999, 276:G315-G321.
58. Wink D.A., Mitchell J.B. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic. Biol. Med. 1998, 25:434-456.
59. Thomas D.D., et al. Chapter 1 - determinants of nitric oxide chemistry: impact of cell signaling processes. Nitric Oxide 2010, 3-25. Academic Press. 2nd edn. L.J. Ignarro (Ed.).
60. Bogdan C. Nitric oxide and the immune response. Nat. Immunol. 2001, 2:907-916.
61. Palmer R.M.J., et al. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988, 333:664-666.
62. Gross S.S., Wolin M.S. Nitric oxide: pathophysiological mechanisms. Annu. Rev. Physiol. 1995, 57:737-769.
63. Marletta M.A. Nitric oxide: biosynthesis and biological significance. Trends Biochem. Sci. 1989, 14:488-492.
64. Moncada S., Higgs E.A. The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol. 2006, 147:S193-S201.
65. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 2001, 88:756-762.
66. Ignarro L.J., et al. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ. Res. 2002, 90:21-28.
67. MacMicking J., et al. Nitric oxide and macrophage function. Annu. Rev. Immunol. 1997, 15:323-350.
68. Nathan C., Shiloh M.U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8841-8848.
69. Frost M.C., et al. Polymers incorporating nitric oxide releasing/generating substances for improved biocompatibility of blood-contactincy medical devices. Biomaterials 2005, 26:1685-1693.
70. Annich G.M., et al. Reduced platelet activation and thrombosis in extracorporeal circuits coated with nitric oxide release polymers. Crit. Care Med. 2000, 28:915-920.
71. Sulemankhil I., et al. Prevention and treatment of virulent bacterial biofilms with an enzymatic nitric oxide-releasing dressing. Antimicrob. Agents Chemother. 2012, 56:6095-6103.
72. Cooke J.P. NO and angiogenesis. Artheroscler. Suppl. 2003, 4:53-60.
73. Jones M.K., et al. Dual actions of nitric oxide on angiogenesis: possible roles of PKC, ERK, and AP-1. Biochem. Biophys. Res. Commun. 2004, 318:520-528.
74. Harding J.L., Reynolds M.M. Metal organic frameworks as nitric oxide catalysts. J. Am. Chem. Soc. 2012, 134:3330-3333.
75. Harding J.L., Reynolds M.M. Composite materials with embedded metal organic framework catalysts for nitric oxide release from bioavailable S-nitrosothiols. J. Mater. Chem. B 2014, 10.1039/C3TB21458C.
76. Cook S., et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007, 115:2426-2434.
77. Kang C.K., et al. Fabrication of biofunctional stents with endothelial progenitor cell specificity for vascular re-endothelialization. Colloids Surf. B: Biointerfaces 2013, 102:744-751.
78. Yang D.Y., et al. The molecular mechanism of mediation of adsorbed serum proteins to endothelial cells adhesion and growth on biomaterials. Biomaterials 2013, 34:5747-5758.
79. Hiob M.A., et al. The use of plasma-activated covalent attachment of early domains of tropoelastin to enhance vascular compatibility of surfaces. Biomaterials 2013, 34:7584-7591.